“Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL)”, J of Skin, vol. 4, no. 5, p. s51, Sep. 2020, doi: 10.25251/skin.4.supp.50.